BCL-XL PROTAC degrader DT2216 synergizes with sotorasib in preclinical models of KRASG12C-mutated cancers

Abstract KRAS mutations are the most common oncogenic drivers. Sotorasib (AMG510), a covalent inhibitor of KRASG12C, was recently approved for the treatment of KRASG12C-mutated non-small cell lung cancer (NSCLC). However, the efficacy of sotorasib and other KRASG12C inhibitors is limited by intrinsi...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Sajid Khan, Janet Wiegand, Peiyi Zhang, Wanyi Hu, Dinesh Thummuri, Vivekananda Budamagunta, Nan Hua, Lingtao Jin, Carmen J. Allegra, Scott E. Kopetz, Maria Zajac-Kaye, Frederic J. Kaye, Guangrong Zheng, Daohong Zhou
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2022-03-01
Colecção:	Journal of Hematology & Oncology
Assuntos:	KRASG12C BCL-XL PROTAC Sotorasib Drug resistance
Acesso em linha:	https://doi.org/10.1186/s13045-022-01241-3
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!